Patent intelligence · AP
AP 832
3-Tetrahydrofuran and tetrohydropyrinol ephynolsporens and analogues.
3-Tetrahydrofuran and tetrohydropyrinol ephynolsporens and analogues.
Patent details — AP 832
- Jurisdiction
- AP
- Status
- expired
- Grant date
- May 3, 2000
- Expiration
- Apr 28, 2020
- Applicant
- BEECHAM GROUP PLC [GB]
- CPC classes
- A61K 31/ 397 A I, A61K 31/ 545 A I, A61K 31/ 546 A I, A61K31/545
Quick answer
AP 832 (3-Tetrahydrofuran and tetrohydropyrinol ephynolsporens and analogues.) is held by BEECHAM GROUP PLC [GB]. Status: expired. Granted May 3, 2000. Expires Apr 28, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BEECHAM GROUP PLC [GB]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 397 A I, A61K 31/ 545 A I, A61K 31/ 546 A I, A61K31/545, A61P 31/ 04 A I, A61P/3104
More from BEECHAM GROUP PLC [GB]
Related pharmaceutical patents in our USPTO index.
-
SA 92120308
تركيبة للاستخدام الموضعي topical composition
expired -
AT E269330
CHEMISCHE VERBINDUNGEN
expired -
EP 1425277
HARNSTOFF-DERIVATE ALS VANILLOID-REZEPTOR-ANTAGONISTEN FÜR DIE SCHMERZBEHANDLUNG
expired -
SA 91110341
مستحضر موضعي لعلاج العدوى بفيروس الحلا (القوباء) Herpesvirus
expired -
HU P0302480
PYRIDINONE DERIVATIVES FOR TREATMENT OF ATHEROSCLEROSIS, PROCESS FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
expired -
AT E245157
3,9-DIAZABICYCLO-(3.3.1)-NONANYLDERIVATE, VERFAHREN UND INTERMEDIATE FÜR IHRE DARSTELLUNG UND SIE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN
expired -
HK 1004528
Dentifrice compositions
expired -
HU P0204410
PYRIMIDINE-4-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE
expired
Related coverage
BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
BioNTech and Genentech have dosed the first patient in the Phase 1 pancreatic cancer mRNA vaccine trial of autogene cevumeran. Earlier Nature data showed immune responses in 8 of 16 patients and established the study as the first mRNA vaccine trial in pancreatic cancer.
Moderna mRNA-1083 Phase 3 data show stronger flu and COVID immune response
Moderna says its combined flu-COVID vaccine mRNA-1083 met Phase 3 primary endpoints with higher immune responses in adults 50 and older. The readout matters for BD teams and investors tracking combo-vaccine competition, FDA posture, and next filing milestones.
Moderna's mRNA-1083 Phase 3 shows stronger flu and COVID immune responses
Moderna's mRNA-1083 posted positive Phase 3 results in adults 50 and older, meeting primary endpoints with stronger immune responses against influenza and SARS-CoV-2 than licensed comparators. The readout strengthens the case for a combined flu-COVID vaccine, but regulatory questions about the separate flu vaccine filing remain relevant for BD teams and investors.
Frequently asked questions
What is US patent 832?
AP 832 (3-Tetrahydrofuran and tetrohydropyrinol ephynolsporens and analogues.) is held by BEECHAM GROUP PLC [GB]. Status: expired. Granted May 3, 2000. Expires Apr 28, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns AP 832?
BEECHAM GROUP PLC [GB] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does AP 832 expire?
Our index shows an expiration date of Apr 28, 2020 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.